您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > ATRA-BA Hybrid
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ATRA-BA Hybrid
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ATRA-BA Hybrid图片
CAS NO:1037543-26-2
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
A prodrug form of all-trans retinoic acid and butyric acid
Cas No.1037543-26-2
Canonical SMILESO=C(/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)C)C)OC2=CC=C(C=C2)COC(CCC)=O
分子式C31H40O4
分子量476.7
溶解度DMSO: 5 mg/ml
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

ATRA-BA hybrid is a mutual prodrug form of all-transretinoic acid and butyric acid .1ATRA-BA hybrid is cleaved to release ATRA and BA in isolated mouse plasma. It inhibits the growth of MDA-MB-231 breast and PC3 prostate cancer cells with GI50values of 0.01 and 1.02 µM, respectively. ATRA-BA (20 µM) has 15-fold greater antiproliferative activity in PC3 cells compared to an equimolar concentration of ATRA and BA.

1.Gediya, L.K., Khandelwal, A., Patel, J., et al.Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitroJ. Med. Chem.51(13)3895-3904(2008)